PeptidePedia The community reference

Custom peptide synthesis (revision 23)

Old revision·15:49, 4 Feb 2026·CounterfeitCato

This is an old revision of this page, as it stood at 15:49, 4 Feb 2026, saved by CounterfeitCato with the summary add the reconstitution-stability sentence with its storage condition. It may differ substantially from the current revision, and any error it contains may since have been corrected.
Custom peptide synthesisCommercial service
InputA sequence and a specification
Priced byLength, scale, purity grade, modifications
Contrast withCatalogue supply of stocked compounds
Topic infobox · conventions

Custom peptide synthesis is the manufacture of a peptide to a sequence and specification supplied by the customer, as distinct from supply of a catalogue item held in stock. It is the ordinary route by which research peptides that are not commercially stocked are obtained.[1]

A custom order is defined by more than a sequence. Scale, purity grade, C-terminal functionality, any modifications such as acylation or cyclisation, salt form, and which determinations will appear on the certificate are all specification items, and a quotation that does not enumerate them is quoting for an underdetermined thing.[2]

Price scales with length, with target purity, and with the difficulty of the sequence — which is not predictable from length alone. A quotation therefore reflects an assessment of synthetic difficulty as much as a price list.[1]

What a specification should fix

[edit]
ItemWhy it matters
Sequence and modificationsDefines the molecule; ambiguity here is fatal
C-terminal formAcid or amide; set by linker choice
Purity gradeDetermines purification effort and price
Salt formTrifluoroacetate counterion or exchanged; affects Peptide content
ScaleNet peptide mass, not solid mass
Determinations on the certificateWhat will actually be reported

The distinction between net peptide mass and solid mass is the one most often left ambiguous. An order for "10 mg" may be filled as 10 mg of solid, which at typical content is rather less peptide, or as solid containing 10 mg of peptide. The two differ by the counterion and water fractions.[2]

Sequence ambiguity is the failure with the largest consequence. One-letter and three-letter codes, D-residue conventions, and non-standard abbreviations for modified residues all vary between houses, and a sequence should be unambiguous on its face. See Peptide.

What a quotation reveals

[edit]

A quotation that names a delivery date, a purity grade and a determination set is a more informative document than one giving only a price. It says the supplier has assessed the sequence rather than applied a per-residue rate.[1]

Declining to quote is also informative and is not a negative signal. Some sequences are genuinely difficult, some require capability a given house does not have, and a house that declines rather than accepting and failing is behaving reasonably.

Quotations for sequences corresponding to compounds under patent, or to controlled substances, raise separate questions that are legal rather than technical. This wiki does not advise on them; see Regulatory status by jurisdiction and Patent expiry and biosimilars.[3]

Documentation for custom work

[edit]

Custom work more often carries fuller documentation than catalogue supply, because the specification was negotiated. Certificates from custom orders in submissions to this wiki more often include mass confirmation, amino acid analysis and an itemised related-substances table than catalogue certificates do.[4]

That is an observation about a self-selected set of submitted documents rather than a general finding about the market, and it should not be read as a comparison between named organisations.

The single most useful field remains the same as for any peptide: whether the document reports enough to let a reader work out how much peptide is in the container. See Peptide content and Underfilling.[2]

See also

References

  1. ^ a b c Behrendt R, White P, Offer J. "Advances in Fmoc solid-phase peptide synthesis." Journal of Peptide Science 22(1):4–27 (2016). PMID 26785684.
  2. ^ a b c United States Pharmacopeia, General Chapter <1503>, Quality Attributes of Synthetic Peptide Drug Substances.
  3. ^ ISO 9001:2015, Quality management systems — Requirements.
  4. ^ PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see Project:Sourcing guidelines).